{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:10:17Z","timestamp":1791670217699,"version":"4.3.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010607","name":"Universit\u00e0 degli Studi di Perugia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010607","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In patients with heart failure with reduced ejection fraction (HFrEF), treatment with sacubitril\u2013valsartan (S\/V) may reverse left ventricular remodeling (rLVR). Whether this effect is superior to that induced by other renin\u2013angiotensin system (RAS) inhibitors is not well known.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      HFrEF patients treated with S\/V (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009795) were compared, by propensity score matching, with a historical cohort of 831 HFrEF patients (non-S\/V group) treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (RAS inhibitors). All patients were also treated with beta-blockers and shared the same protocol with repeat echocardiogram 8\u201312 months after starting therapy. The difference-in-difference (DiD) analysis was used to evaluate the impact of S\/V on CR indices between the two groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After propensity score matching, compared to non-S\/V group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009354), S\/V group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009354) showed a relative greater reduction in end-diastolic and end-systolic volume index (ESVI), and greater increase in ejection fraction (DiD estimator\u2009=\u2009\u2009+\u20095.42 mL\/m\n                      <jats:sup>2<\/jats:sup>\n                      ,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0005;\u2009+\u20094.68 mL\/m\n                      <jats:sup>2<\/jats:sup>\n                      ,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0009, and\u2009+\u20091.76%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.002, respectively). Reverse LVR (reduction in ESVI\u2009\u2265\u200915% from baseline) was more prevalent in S\/V than in non-S\/V group (34% vs 26%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.017), while adverse LVR (aLVR, increase in ESVI at follow-up\u2009\u2265\u200915%) was more frequent in non-S\/V than in S\/V (16% vs 7%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). The beneficial effect of S\/V on CR over other RAS inhibitors was appreciable across a wide range of patient\u2019s age and baseline end-diastolic volume index, but it tended to attenuate in more dilated left ventricles (\n                      <jats:italic>P<\/jats:italic>\n                      for interaction\u2009=\u2009NS for both).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In HFrEF patients treated with beta-blockers, sacubitril\/valsartan is associated with a relative greater benefit in LV reverse remodeling indices than other RAS inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00392-023-02306-0","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T03:02:52Z","timestamp":1695265372000},"page":"856-865","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Effect of sacubitril\/valsartan on cardiac remodeling compared with other renin\u2013angiotensin system inhibitors: a difference-in-difference analysis of propensity-score matched samples"],"prefix":"10.1007","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9296-4397","authenticated-orcid":false,"given":"Erberto","family":"Carluccio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank L.","family":"Dini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Correale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Dattilo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Ciccarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Vannuccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Sforna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Pacileo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Masarone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Scelsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Ghio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Gabriele","family":"Tocchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Mercurio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natale Daniele","family":"Brunetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savina","family":"Nodari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Palazzuoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Working Group on Heart Failure of the Italian Society of Cardiology","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,21]]},"reference":[{"key":"2306_CR1","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR et al (2022) 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines. J Am Coll Cardiol 79:e263\u2013e421. https:\/\/doi.org\/10.1016\/j.jacc.2021.12.012","journal-title":"J Am Coll Cardiol"},{"key":"2306_CR2","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O et al (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599\u20133726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"2306_CR3","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jcmg.2010.10.008","volume":"4","author":"MA Konstam","year":"2011","unstructured":"Konstam MA, Kramer DG, Patel AR, Maron MS, Udelson JE (2011) Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. JACC Cardiovasc Imaging 4:98\u2013108. https:\/\/doi.org\/10.1016\/j.jcmg.2010.10.008","journal-title":"JACC Cardiovasc Imaging"},{"key":"2306_CR4","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jacc.2010.05.011","volume":"56","author":"DG Kramer","year":"2010","unstructured":"Kramer DG, Trikalinos TA, Kent DM, Antonopoulos GV, Konstam MA, Udelson JE (2010) Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol 56:392\u2013406. https:\/\/doi.org\/10.1016\/j.jacc.2010.05.011","journal-title":"J Am Coll Cardiol"},{"key":"2306_CR5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.aogh.2013.12.006","volume":"80","author":"JZ Goldfinger","year":"2014","unstructured":"Goldfinger JZ, Nair AP (2014) Myocardial recovery and the failing heart: medical, device and mechanical methods. Ann Glob Health 80:55\u201360. https:\/\/doi.org\/10.1016\/j.aogh.2013.12.006","journal-title":"Ann Glob Health"},{"key":"2306_CR6","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.jacc.2005.09.064","volume":"47","author":"E Carluccio","year":"2006","unstructured":"Carluccio E, Biagioli P, Alunni G, Murrone A, Giombolini C, Ragni T, Marino PN, Reboldi G, Ambrosio G (2006) Patients with hibernating myocardium show altered left ventricular volumes and shape, which revert after revascularization: evidence that dyssynergy might directly induce cardiac remodeling. J Am Coll Cardiol 47:969\u2013977. https:\/\/doi.org\/10.1016\/j.jacc.2005.09.064","journal-title":"J Am Coll Cardiol"},{"key":"2306_CR7","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.jcmg.2011.07.006","volume":"4","author":"E Carluccio","year":"2011","unstructured":"Carluccio E, Biagioli P, Alunni G, Murrone A, Pantano P, Biscottini E, Zuchi C, Zingarini G, Cavallini C, Ambrosio G (2011) Presence of extensive LV remodeling limits the benefits of CRT in patients with intraventricular dyssynchrony. JACC Cardiovasc Imaging 4:1067\u20131076. https:\/\/doi.org\/10.1016\/j.jcmg.2011.07.006","journal-title":"JACC Cardiovasc Imaging"},{"key":"2306_CR8","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/01.cir.86.2.431","volume":"86","author":"MA Konstam","year":"1992","unstructured":"Konstam MA, Rousseau MF, Kronenberg MW, Udelson JE, Melin J, Stewart D, Dolan N, Edens TR, Ahn S, Kinan D et al (1992) Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD investigators. Circulation 86:431\u2013438. https:\/\/doi.org\/10.1161\/01.cir.86.2.431","journal-title":"Circulation"},{"key":"2306_CR9","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/s0002-9149(99)00059-4","volume":"83","author":"BD Lowes","year":"1999","unstructured":"Lowes BD, Gill EA, Abraham WT, Larrain JR, Robertson AD, Bristow MR, Gilbert EM (1999) Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol 83:1201\u20131205. https:\/\/doi.org\/10.1016\/s0002-9149(99)00059-4","journal-title":"Am J Cardiol"},{"key":"2306_CR10","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/s0735-1097(02)02063-6","volume":"40","author":"M Wong","year":"2002","unstructured":"Wong M, Staszewsky L, Latini R, Barlera S, Volpi A, Chiang YT, Benza RL, Gottlieb SO, Kleemann TD, Rosconi F et al (2002) Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol 40:970\u2013975. https:\/\/doi.org\/10.1016\/s0735-1097(02)02063-6","journal-title":"J Am Coll Cardiol"},{"key":"2306_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105573","volume":"169","author":"J Bao","year":"2021","unstructured":"Bao J, Kan R, Chen J, Xuan H, Wang C, Li D, Xu T (2021) Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction: a systematic review and network meta-analysis of randomized clinical trials. Pharmacol Res 169:105573. https:\/\/doi.org\/10.1016\/j.phrs.2021.105573","journal-title":"Pharmacol Res"},{"key":"2306_CR12","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJV McMurray","year":"2014","unstructured":"McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa1409077","journal-title":"N Engl J Med"},{"key":"2306_CR13","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1001\/jama.2019.12843","volume":"322","author":"AS Desai","year":"2019","unstructured":"Desai AS, Solomon SD, Shah AM, Claggett BL, Fang JC, Izzo J, McCague K, Abbas CA, Rocha R, Mitchell GF et al (2019) Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 322:1077\u20131084. https:\/\/doi.org\/10.1001\/jama.2019.12843","journal-title":"JAMA"},{"key":"2306_CR14","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1001\/jama.2019.12821","volume":"322","author":"JL Januzzi Jr","year":"2019","unstructured":"Januzzi JL Jr, Prescott MF, Butler J, Felker GM, Maisel AS, McCague K, Camacho A, Pina IL, Rocha RA, Shah AM et al (2019) Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA 322:1085\u20131095. https:\/\/doi.org\/10.1001\/jama.2019.12821","journal-title":"JAMA"},{"key":"2306_CR15","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1161\/CIRCULATIONAHA.118.037077","volume":"139","author":"DH Kang","year":"2019","unstructured":"Kang DH, Park SJ, Shin SH, Hong GR, Lee S, Kim MS, Yun SC, Song JM, Park SW, Kim JJ (2019) Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation. Circulation 139:1354\u20131365. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.037077","journal-title":"Circulation"},{"key":"2306_CR16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ijcard.2022.01.004","volume":"350","author":"E Carluccio","year":"2022","unstructured":"Carluccio E, Dini FL, Bitto R, Ciccarelli M, Correale M, D\u2019Agostino A, Dattilo G, Ferretti M, Grelli A, Guida S et al (2022) Benefit from sacubitril\/valsartan is associated with hemodynamic improvement in heart failure with reduced ejection fraction: an echocardiographic study. Int J Cardiol 350:62\u201368. https:\/\/doi.org\/10.1016\/j.ijcard.2022.01.004","journal-title":"Int J Cardiol"},{"key":"2306_CR17","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1002\/ehf2.13779","volume":"9","author":"FL Dini","year":"2022","unstructured":"Dini FL, Carluccio E, Bitto R, Ciccarelli M, Correale M, D\u2019Agostino A, Dattilo G, Ferretti M, Grelli A, Guida S et al (2022) Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril\/valsartan. ESC Heart Fail 9:1107\u20131117. https:\/\/doi.org\/10.1002\/ehf2.13779","journal-title":"ESC Heart Fail"},{"key":"2306_CR18","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/ejhf.664","volume":"19","author":"S Ghio","year":"2017","unstructured":"Ghio S, Guazzi M, Scardovi AB, Klersy C, Clemenza F, Carluccio E, Temporelli PL, Rossi A, Faggiano P, Traversi E et al (2017) Different correlates but similar prognostic implications for right ventricular dysfunction in heart failure patients with reduced or preserved ejection fraction. Eur J Heart Fail 19:873\u2013879. https:\/\/doi.org\/10.1002\/ejhf.664","journal-title":"Eur J Heart Fail"},{"key":"2306_CR19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/ehjci\/jev014","volume":"16","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging 16:233\u2013270. https:\/\/doi.org\/10.1093\/ehjci\/jev014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2306_CR20","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/j.jacc.2017.01.058","volume":"69","author":"OS Andersen","year":"2017","unstructured":"Andersen OS, Smiseth OA, Dokainish H, Abudiab MM, Schutt RC, Kumar A, Sato K, Harb S, Gude E, Remme EW et al (2017) Estimating left ventricular filling pressure by echocardiography. J Am Coll Cardiol 69:1937\u20131948. https:\/\/doi.org\/10.1016\/j.jacc.2017.01.058","journal-title":"J Am Coll Cardiol"},{"key":"2306_CR21","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 46:399\u2013424. https:\/\/doi.org\/10.1080\/00273171.2011.568786","journal-title":"Multivariate Behav Res"},{"key":"2306_CR22","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1001\/jama.2014.16153","volume":"312","author":"JB Dimick","year":"2014","unstructured":"Dimick JB, Ryan AM (2014) Methods for evaluating changes in health care policy: the difference-in-differences approach. JAMA 312:2401\u20132402. https:\/\/doi.org\/10.1001\/jama.2014.16153","journal-title":"JAMA"},{"key":"2306_CR23","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1002\/sim.1815","volume":"23","author":"P Royston","year":"2004","unstructured":"Royston P, Sauerbrei W (2004) A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials. Stat Med 23:2509\u20132525. https:\/\/doi.org\/10.1002\/sim.1815","journal-title":"Stat Med"},{"key":"2306_CR24","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1002\/ejhf.1234","volume":"20","author":"M Komajda","year":"2018","unstructured":"Komajda M, Bohm M, Borer JS, Ford I, Tavazzi L, Pannaux M, Swedberg K (2018) Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis. Eur J Heart Fail 20:1315\u20131322. https:\/\/doi.org\/10.1002\/ejhf.1234","journal-title":"Eur J Heart Fail"},{"key":"2306_CR25","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012272","volume":"8","author":"Y Wang","year":"2019","unstructured":"Wang Y, Zhou R, Lu C, Chen Q, Xu T, Li D (2019) Effects of the angiotensin-receptor neprilysin inhibitor on cardiac reverse remodeling: meta-analysis. J Am Heart Assoc 8:e012272. https:\/\/doi.org\/10.1161\/JAHA.119.012272","journal-title":"J Am Heart Assoc"},{"key":"2306_CR26","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1161\/CIRCULATIONAHA.121.054892","volume":"144","author":"KF Docherty","year":"2021","unstructured":"Docherty KF, Campbell RT, Brooksbank KJM, Dreisbach JG, Forsyth P, Godeseth RL, Hopkins T, Jackson AM, Lee MMY, McConnachie A et al (2021) Effect of neprilysin inhibition on left ventricular remodeling in patients with asymptomatic left ventricular systolic dysfunction late after myocardial infarction. Circulation 144:199\u2013209. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.054892","journal-title":"Circulation"},{"key":"2306_CR27","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/ehf2.14155","volume":"10","author":"GE Mandoli","year":"2023","unstructured":"Mandoli GE, Pastore MC, Giannoni A, Benfari G, Dini FL, Rosa G, Pugliese NR, Taddei C, Correale M, Brunetti ND et al (2023) Deformation imaging by strain in chronic heart failure over sacubitril-valsartan: a multicenter echocardiographic registry. ESC Heart Fail 10:846\u2013857. https:\/\/doi.org\/10.1002\/ehf2.14155","journal-title":"ESC Heart Fail"},{"key":"2306_CR28","doi-asserted-by":"publisher","first-page":"oeab046","DOI":"10.1093\/ehjopen\/oeab046","volume":"2","author":"MC Pastore","year":"2022","unstructured":"Pastore MC, Mandoli GE, Giannoni A, Benfari G, Dini FL, Pugliese NR, Taddei C, Correale M, Brunetti ND, Carluccio E et al (2022) Sacubitril\/valsartan reduces indications for arrhythmic primary prevention in heart failure with reduced ejection fraction: insights from DISCOVER-ARNI, a multicenter Italian register. Eur Heart J Open. 2:oeab046. https:\/\/doi.org\/10.1093\/ehjopen\/oeab046","journal-title":"Eur Heart J Open."}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-023-02306-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-023-02306-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-023-02306-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T03:05:02Z","timestamp":1716260702000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-023-02306-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,21]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2306"],"URL":"https:\/\/doi.org\/10.1007\/s00392-023-02306-0","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,21]]},"assertion":[{"value":"10 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}